Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Koiji SasakiHagop M KantarjianKiyomi MoritaNicholas James ShortMarina KonoplevaNitin JainFarhad RavandiGuillermo Garcia ManeroSa WangJoseph D KhouryJeffrey L JorgensenRichard E ChamplinIssa F KhouriPartow KebriaeiHeather M SchroederMaria KhouriRebecca GarrisKoichi TakahashiSusan M O'BrienElias J JabbourPublished in: Cancer (2021)
Hyper-CVAD + ofatumumab was associated with better outcomes than hyper-CVAD + Rituximab among patients with newly diagnosed Philadelphia chromosome-negative ALL.